CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma

Abstract Background Patients with severe, uncontrolled asthma, particularly those with a non-eosinophilic phenotype, have a great unmet need for new treatments that act on a broad range of inflammatory pathways in the airway. Tezepelumab is a human monoclonal antibody that blocks the activity of thy...

Full description

Bibliographic Details
Main Authors: Claire Emson, Sarah Diver, Latifa Chachi, Ayman Megally, Cherrie Small, John Downie, Jane R. Parnes, Karin Bowen, Gene Colice, Chris E. Brightling
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Respiratory Research
Subjects:
Asthma
Tezepelumab
T2 inflammation
TSLP
Online Access:http://link.springer.com/article/10.1186/s12931-020-01513-x

Internet

http://link.springer.com/article/10.1186/s12931-020-01513-x

Similar Items